Objective To assess the effectiveness of acupunctures in treatment of primary dysmenorrhea by using network meta-analysis. Methods Databases including the PubMed, EMbase, The Cochrane Library (Issue 6, 2016), CBM, CNKI and WanFang Data were searched for relevant clinical randomized controlled trials (RCTs) comparing acupunctures with ibuprofen or other kinds of acupuncture from inception to July 6th 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed by using Stata 13.0 and WinBugs 1.43 software. Results A total of 56 RCTs involving 4 600 PD patients were included. The results of network meta-analysis showed that: for the clinical effects: simple acupuncture, acupuncture plus moxa-moxibustion, acupuncture plus indirect-moxibustion, electroacupuncture, warm-acupuncture and electroacupuncture plus warm-acupuncture were superior to ibuprofen, acupuncture plus moxa-moxibustion, acupuncture plus indirect-moxibustion and warm-acupuncture were superior to simple acupuncture. For VAS score, there was no significant difference among all treatments. Simple acupuncture and ibuprofen were superior to acupuncture plus indirect-moxibustion in dysmenorrhea symptom scores. Conclusion The included 6 kinds of acupunctures are superior to ibuprofen and different acupunctures have different advantages in the treatment of PD. When selecting treatment regimen, it is better to consider the clinical situation and TCM syndrome differentiation.
目的 探討氨基葡萄糖聯合布洛芬治療髖關節骨關節炎的臨床療效。 方法 2011年9月－2012年1月采用前瞻性隨機對照臨床試驗，將198例輕、中度髖關節骨關節炎患者隨機分入試驗組及對照組。試驗組采用氨基葡萄糖（750 mg， 2次/d口服，療程1個月）聯合布洛芬（0.3 g，2次/d口服，療程2周），對照組則單用布洛芬（0.3 g，2次/d口服，療程2周）；分別于服藥后0、2、4、8及12周時采用加拿大西安大略和麥克瑪斯特大學骨關節炎指數（WOMAC）進行療效評價。并對惡心、嘔吐、皮疹等藥物不良反應進行觀察。 結果 試驗組與對照組WOMAC各項評分從第2周開始較0周明顯下降，而兩組患者間在0周及2周時WOMAC評分無統計學差異：0周總評分（45.3、45.0分，P=0.225），2周總評分（37.3、37.6分，P=0.329）。但對照組WOMAC各項評分從第4周開始逐漸呈現上升趨勢，而試驗組到第12周仍呈現持續性下降趨勢。總不良反應發生率為7.0%，其中試驗組總不良反應發生率為9.5%，但不良反應輕微，未予特殊處理而自行消失。 結論 氨基葡萄糖聯合布洛芬可有效緩解早、中期髖關節骨關節炎各項臨床癥狀，療效確切，不良反應較少，且停藥后仍持續表現出治療效果。而單用布洛芬可短期緩解骨關節炎癥，但停藥后癥狀逐漸復現。
ObjectiveTo systematically review the efficacy and safety of ibuprofen for premature infants with patent ductus arteriosus. MethodsDatabases including PubMed, Ovid-EMbase, The Cochrane Library (Issue 11, 2014), CNKI, WanFang Data and VIP were searched to collect randomized controlled trials (RCTs) and quasi-RCTs about ibuprofen for premature infants with patent ductus arteriosus from inception to December 2014. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was conducted by RevMan 5.3 software. ResultsA total of 37 RCTs, involving 2 370 patients were included. The results of meta-analysis showed that, compared with the placebo/blank group, ibuprofen could increase the closure rate of PDA (LBWI:RR=1.93, 95%CI 1.25 to 2.99，P=0.003; VLBW:RR=1.23, 95%CI 1.02 to 1.48, P=0.03; ELBWI:RR=2.86, 95%CI 1.51 to 5.41, P=0.001) and decrease the incidence of sepsis (VLBW:RR=0.21, 95%CI 0.07 to 0.64，P=0.006); Compared with the indometacin groups, ibuprofen could decrease the incidence of the increase of serum creatinine (LBWI:RR=0.11, 95%CI 0.04 to 0.37, P=0.000 2), NEC (LBWI, RR=0.52, 95%CI 0.29 to 0.95, P=0.03) and oliguria (LBWI: RR=0.30, 95%CI 0.16 to 0.56, P=0.000 2; VLBW:RR=1.40, 95%CI 1.03 to 1.92, P=0.03); Compared with the intravenous ibuprofen, Oral ibuprofen could increase the closure rate of PDA (VLBW: RR=1.35, 95%CI 1.12 to 1.62, P=0.002; ELBWI, RR=1.42, 95%CI 1.07 to 1.87, P=0.01). ConclusionCurrent evidence shows that there is not indeterminate between ibuprofen and paracetamol groups. Compared with other general drugs, ibuprofen has an advantage over curing PDA and obviously reduces side effects. Due to the limited quality and quantity of included studies, more high quality studies are needed to verify the above conclusion.